ACS OMEGA

http://pubs.acs.org/journal/acsodf

Addition/Correction

Correction to "Febuxostat Prevents the Cytotoxicity of Propofol in Brain Endothelial Cells"

Jianli Hao, Weiqing Zhang, Rui Tong, and Zeqing Huang*

ACS Omega **2021**, *6* (8), 5471−5478. DOI: 10.1021/acsomega.0c05708

Cite This: *ACS Omega* 2022, 7, 13395−13396

Read Online

ACCESS | Metrics & More | Article Recommendations

After our paper was published online, we discovered that the following details for the "Materials and Methods" section are missing. The erratum does not have an effect on the results or conclusions drawn in the text.

1. Regarding the identity of the source of the propofol and febuxostat, as well as the specific details on how the treatment concentrations for the study were determined:
   (1) Propofol (#PHR1663) and Febuxostat (#SML1285) were purchased from Sigma-Aldrich (Burlington, USA).
   (2) 2% propofol has been widely used for in vitro cell cultures in previous studies.[1]
   (3) Cell viability experiments in Figure 1B were performed to screen the optimal concentrations of febuxostat used in this study.
2. Regarding the manufacturer and sequences of the primers used in the RT-PCR reaction and the cycles of PCR performed:
   The primers of target genes were purchased from Genscript Corp., China. The sequences of primers are shown in the following Table 1. A total of 40 cycles were performed for real-time PCR.

REFERENCES

(1) Obata, Y.; Adachi, Y. U.; Suzuki, K.; Itagaki, T.; Kato, H.; Satomoto, M.; Nakajima, Y. The Influence of Differences in Solvents and Concentration on the Efficacy of Propofol at Induction of Anesthesia. *Anesthesiol. Res. Pract.* **2016**, *2016*, 9178523.

Received: March 21, 2022
Published: April 8, 2022

Table 1. Primer Sequences

target gene	upstream sequence (5′-3′)	downstream sequence (5′-3′)
IL-6	5′- TACCACTTCACAAGTCGGAGGC-3′	5′- CTGCAAGTGCATCATCGTTGTTC-3′
IL-12	5′- ACGAGAGTTGCCTGGCTACTAG-3′	5′- CCTCATAGATGCTACCAAGGCAC-3′
TNF-α	5′- GGTGCCTATGTCTCAGCCTCTT −3′	5′- GCCATAGAACTGATGAGAGGGAG-3′
VCAM-1	5′- GCTATGAGGATGGAAGACTCTGG-3′	5′- ACTTGTGCAGCCACCTGAGATC-3′
E-selectin	5′- GGACACCACAAATCCCAGTCTG-3′	5′- TCGCAGGAGAACTCACAACTGG-3′
CXCL-1	5′- TCCAGAGCTTGAAGGTGTTGCC-3′	5′- AACCAAGGGAGCTTCAGGGTCA-3′
PDPN	5′- ACAACCACAGGTGCTACTGGAG-3′	5′- GTTGCTGAGGTGGACAGTTCCT-3′
CXCL-8	5′- TCAATGCCTGAAGACCCTGCCAA-3′	5′- TGGGTTCTTCCGTTGAGGGACAGC-3′
COX-2	5′- GCGACATACTCAAGCAGGAGCA-3′	5′- AGTGGTAACCGCTCAGGTGTTG-3′
KLF6	5′- GGAAGGTTGTGAGTGGCGTTTTG-3′	5′- AGGTGGTCAGACCTGGAGAAAC-3′
GAPDH	5′- CATCACTGCCACCCAGAAGACTG 3′,	5′- ATGCCAGTGAGCTTCCCGTTCAG-3′

https://doi.org/10.1021/acsomega.2c01716
ACS Omega 2022, 7, 13395−13396